After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

Vaccines represent the single most cost-efficient and equitable way to combat and eradicate
infectious diseases. While traditional licensed vaccines consist of either …

Modern drug delivery technology began in 1952 with the advent of the Spansule® sustained-
release capsule technology, which can deliver a drug for 12 h after oral administration …

Background Whether a broadly neutralizing antibody (bnAb) can be used to prevent human
immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk …

With rapid advances in understanding molecular pathogenesis of human diseases in the era
of genome sciences and systems biology, it is anticipated that increasing numbers of …

In this review we intend to provide a relatively comprehensive summary of the work of
supramolecular hydrogelators after 2004 and to put emphasis particularly on the …

Background Antiretroviral preexposure prophylaxis has been shown to reduce the risk of
human immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting …

HIV infection can be effectively treated by lifelong administration of combination antiretroviral
therapy, but an effective vaccine will likely be required to end the HIV epidemic. Although the …

Background More than 1· 8 million new cases of HIV-1 infection were diagnosed worldwide
in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been …

Antiviral activities of antibodies may either be dependent only on interactions between the
antibody and cognate antigen, as in binding and neutralization of an infectious virion, or …